Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The stockholders of both Inhibitex and FermaVir have approved the companies' merger agreement.
Subscribe to our email newsletter
The transaction adds FV-100, an orally bioavailable bicyclic nucleoside analogue for the treatment of shingles and a series of preclinical compounds for the treatment of human cytomegalovirus disease to the Inhibitex pipeline.
Russell Plumb, president and CEO of Inhibitex, said: “The closing of this transaction represents another significant step forward in our effort to build a diverse pipeline of high-value, differentiated anti-infectives, each of which has the potential to improve upon the standard of care.”